Our profiling and comparison in the steps of conolidine and cannabidiol with identified pharmacological agents predicted a MOA shared with Cav2.2 channel blocker, ω-conotoxin CVIE. In 2011, the halls of the Scripps Investigate Institute in Jupiter, Florida witnessed the inception of the scientific journey that may redefine our knowledge https://proleviate.com/people-are-using-proleviate-for-their-daily-pain-management/